Lewis Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Lewis Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$910K	Sell	24,325 -1,830	-7%	-$68K	0.32%	72
2026 Q1	$950K	Buy	26,155 +50	+0.2%	+$2.23K	0.39%	63
2025 Q4	$1.22M	Sell	26,105 -3,570	-12%	-$159K	0.49%	49
2025 Q3	$1.24M	Buy	29,675 +11,275	+61%	+$361K	0.51%	47
2025 Q2	$529K	Sell	18,400 -1,600	-8%	-$49.4K	0.25%	98
2025 Q1	$671K	Buy	20,000 +10,220	+104%	+$382K	0.55%	48
2024 Q4	$500K	Sell	9,780 -2,395	-20%	-$134K	0.38%	64
2024 Q3	$622K	Sell	12,175 -220	-2%	-$11.3K	0.45%	58
2024 Q2	$555K	Buy	+12,395	New	+$572K	0.42%	56

Other funds holding CRNX

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

Lewis Asset Management's CRNX Position: Q2 2026 in Review

Lewis Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 7% in Q2 2026, selling an estimated $68K and leaving 24,325 shares worth $910K. The position accounts for 0.32% of the portfolio, ranked #72.

Lewis Asset Management first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.24M in Q3 2025. 48 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Lewis Asset Management held 24,325 shares of Crinetics Pharmaceuticals worth $910K as of Q2 2026.
Lewis Asset Management sold 1,830 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $68K.
Crinetics Pharmaceuticals made up 0.32% of Lewis Asset Management's portfolio in Q2 2026, its #72 holding.
Lewis Asset Management first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Lewis Asset Management's Crinetics Pharmaceuticals position peaked at $1.24M in Q3 2025.
48 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Lewis Asset Management's 13F filing for Q2 2026, filed 21 Jul 2026.